Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren’s syndrome in mice
暂无分享,去创建一个
N. Zhang | J. Chiorini | W. Swaim | S. Afione | Arif Karim | B. Warner | P. Yu | D. Bloch | Z. Lai | M. C. Guimaro | C. Nguyen | A. Voigt | H. Yin | D. Michael | Javier Cabrera-Perez | Lovika Kalra | Lauren Aber
[1] S. Reppe,et al. Elevated cytokine levels in tears and saliva of patients with primary Sjögren’s syndrome correlate with clinical ocular and oral manifestations , 2019, Scientific Reports.
[2] C. Webber,et al. Antiviral activity of bone morphogenetic proteins and activins , 2018, Nature Microbiology.
[3] Junji Xu,et al. Effect of Bone Morphogenetic Protein 6 on Immunomodulatory Functions of Salivary Gland-Derived Mesenchymal Stem Cells in Sjögren's Syndrome. , 2018, Stem cells and development.
[4] Yingying Su,et al. Bone Morphogenetic Protein 6 Inhibits the Immunomodulatory Property of BMMSCs via Id1 in Sjögren's Syndrome , 2018, Stem cells international.
[5] J. Chiorini,et al. Cross-contamination of the human salivary gland HSG cell line with HeLa cells: A STR analysis study. , 2018, Oral diseases.
[6] L. Criswell,et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts , 2017, Arthritis & rheumatology.
[7] J. Chiorini,et al. Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice , 2016, Proceedings of the National Academy of Sciences.
[8] N. Billestrup,et al. Inflammatory Cytokines Stimulate Bone Morphogenetic Protein-2 Expression and Release from Pancreatic Beta Cells. , 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[9] R. Priori,et al. Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms , 2015, Biology of Sex Differences.
[10] Zuping He,et al. The Function and Regulation of BMP6 in Various Kinds of Stem Cells. , 2015, Current pharmaceutical design.
[11] S. Cha,et al. Mouse Models of Primary Sjogren's Syndrome. , 2015, Current pharmaceutical design.
[12] J. Chiorini,et al. Matriptase Deletion Initiates a Sjögren’s Syndrome-Like Disease in Mice , 2014, PloS one.
[13] G. Illei,et al. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice. , 2013, Arthritis and rheumatism.
[14] Lingying Ye,et al. Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. , 2013, American journal of physiology. Lung cellular and molecular physiology.
[15] A. Bullock,et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. , 2013, ACS chemical biology.
[16] P. ten Dijke,et al. BMP signaling in vascular diseases , 2012, FEBS letters.
[17] J. Nickel,et al. Promiscuity and specificity in BMP receptor activation , 2012, FEBS letters.
[18] J. Chiorini,et al. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome , 2012, Arthritis Research & Therapy.
[19] L. Criswell,et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. , 2011, Arthritis and rheumatism.
[20] A. Tzioufas,et al. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome , 2010, Nature Reviews Rheumatology.
[21] C. Hong,et al. Applications of small molecule BMP inhibitors in physiology and disease. , 2009, Cytokine & growth factor reviews.
[22] Tomokazu Fukuda,et al. BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.
[23] X. Mariette,et al. Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. , 2007, Arthritis and rheumatism.
[24] B. O'Connell,et al. Morphological and functional differentiation of HSG cells: Role of extracellular matrix and trpc 1 , 2007, Journal of cellular physiology.
[25] S. Nielsen,et al. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab , 2006, Clinical Rheumatology.
[26] S. Cha,et al. Sjögren's Syndrome‐Like Disease of C57BL/6.NOD‐Aec1 Aec2 Mice: Gender Differences in Keratoconjunctivitis Sicca Defined by a Cross‐Over in the Chromosome 3 Aec1 Locus , 2006, Scandinavian journal of immunology.
[27] Brij B. Singh,et al. A Role for AQP5 in Activation of TRPV4 by Hypotonicity , 2006, Journal of Biological Chemistry.
[28] C. Eng,et al. From developmental disorder to heritable cancer: it's all in the BMP/TGF-β family , 2003, Nature Reviews Genetics.
[29] M. Humphreys-Beher,et al. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. , 2002, Arthritis and rheumatism.
[30] Carissa M Krane,et al. Salivary Acinar Cells from Aquaporin 5-deficient Mice Have Decreased Membrane Water Permeability and Altered Cell Volume Regulation* , 2001, The Journal of Biological Chemistry.
[31] R. Kiss,et al. Abnormal Distribution of Aquaporin-5 Water Channel Protein in Salivary Glands from Sjögren’s Syndrome Patients , 2001, Laboratory Investigation.
[32] J. Massagué,et al. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.
[33] J. Massagué,et al. Determinants of specificity in TGF-beta signal transduction. , 1998, Genes & development.
[34] R. Fox,et al. Sjögren's syndrome , 1995, The Lancet.
[35] R. Fox,et al. Sjögren's syndrome. , 1994, Clinics in dermatology.
[36] Charles C Hong,et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. , 2008, Nature chemical biology.
[37] C. Eng,et al. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. , 2003, Nature reviews. Genetics.
[38] J. Massagué,et al. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. , 1999, Nature.